1Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak - 124001, India
2Department of Microbiology, Kalpana Chawla Government Medical College, Karnal, India
3Department of Microbiology, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak - 124001, India
4Department of Chemistry and Biochemistry, Sharda School of Basic Sciences and Research, Sharda University, Greater Noida, India
The data on the poor outcomes of COVID-19 patients pertaining to their comorbidities is scarce in Indian population. We studied 331 COVID-19 patients admitted to PGIMS, Rohtak, of which 106 were with comorbidities and 225 patients without any comorbid conditions (controls). Among 225 patients without comorbidities, the average length of stay in hospital was ˜3.9 days, while patients (n=106) with comorbidities stayed for almost double time (average 7.4 days). Among 106 hospitalized patients with comorbidities, 61 (57.4%) received oxygen support, with an average intake of 6.5 L/min of oxygen, while 29 of 225 (12.8%) controls received an average 3.1 L/min of oxygen. Out 106 patients with comorbidities 49 (46.2%) required ICU admission compared to 18 (8%) of 225 controls. The mortality in patients with comorbidities was 35.8% (38/106), which was higher than patients with no comorbidities (5.7%, 13/225). The Kaplan-Meier survival curve indicated poor survival trends in COVID-19 patients with comorbidities, as compared to those without comorbidities. Overall, this study demonstrates that comorbidities, like diabetes, hypertension, chronic cardiac disease, chronic kidney disease, chronic pulmonary, thyroid disorders, etc. are associated with severe COVID-19 disease progression.
Covid-19, Clinical features, Comorbidities, SARS-CoV-2, Diabetes, Hypertension
